查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1737205

全球头颈癌药物市场：市场规模（按药物、治疗类型、给药途径、最终用户和地区划分）、未来预测

Global Head And Neck Cancer Drugs Therapeutics Market Size By Therapeutic, By Therapy Type, By Route Of Administration, By End-User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

头颈癌治疗药物市场规模及预测

2024 年头颈癌药物市场规模价值 19.3 亿美元，预计到 2032 年将达到 33.9 亿美元，2026 年至 2032 年的复合年增长率为 7.30%。

头颈癌药物包括一系列专门用于控制和治疗头颈部（包括口腔、咽喉、喉头和鼻腔）癌症的药物治疗方法。

这包括一系列治疗类别，包括化疗、免疫疗法、标靶治疗和放射线治疗。

这些药物主要用于肿瘤学治疗被诊断为头颈癌的患者，这种疾病通常与吸烟、饮酒和人类乳突病毒 (HPV) 感染等风险因素有关。

头颈癌通常与吸烟、饮酒和人类乳突病毒 (HPV) 感染等风险因素有关。

人们对头颈癌认识的提高和精准医疗的进步正在推动对标靶治疗的需求，使得该市场对于解决全球重大健康问题至关重要。

全球头颈癌药物市场动态

影响全球头颈癌药物市场的关键市场动态包括：

关键市场驱动因素

头颈癌发生率上升：根据美国国家癌症美国(NCI) 的数据，预计2024年美国将新增66,470例口腔癌、咽癌和喉癌病例，约占新增癌症病例总数的3.4%。吸烟、饮酒和HPV感染等生活型态因素导致头颈癌发生率上升，是治疗药物需求的主要驱动因素。

治疗方案的进步：药物开发的不断创新，尤其是标靶治疗和免疫疗法，正在提高治疗效果并提高采用率。

提高意识和筛检计画：大众对头颈癌的认识不断提高，并努力促进早期发现和定期筛检，正在鼓励更多患者寻求治疗选择。

增加研发投资：製药公司投入大量资源进行新治疗方法的研究和临床试验，推动市场成长。

医疗保健基础设施的改善：医疗保健设施和肿瘤服务的扩展，特别是在发展中地区，促进了抗癌药物的获取，并促进了市场的扩大。

主要挑战

治疗费用高昂：晚期癌症治疗的高昂费用会限制患者获得治疗的机会，并导致医疗服务可用性的差异。

副作用和毒性：某些抗癌药物可能产生严重的副作用和长期毒性，导致患者无法坚持治疗方法。

监管障碍：新疗法的严格监管和冗长的核准流程可能会减缓市场进入速度，并阻碍患者及时获得创新治疗方法。

新兴市场认知度低：许多新兴国家缺乏认知度和医疗保健基础设施不足可能会限制现有治疗方法的采用。

来自替代疗法的竞争：替代疗法（包括自然疗法和补充疗法）的兴起可能对传统癌症治疗构成挑战。

主要趋势

转向个人化医疗：更重视基于个人基因图谱和生物标记的个人化治疗计划，从而提高头颈癌治疗的有效性。

将科技融入护理：数位健康科技和远端医疗的结合正在改善病患管理和治疗方法的依从性。

合作与伙伴关係：製药公司、研发机构和医疗保健提供者之间加强合作将加速药物开发并促进创新。

注重联合治疗：采用多种治疗方式的联合治疗趋势由于患者治疗效果的改善和抵抗力的降低而越来越受欢迎。

生物标记检测的使用日益增多：生物标记检测在患者分层中的使用日益增多，对于确定头颈癌最有效的治疗方法至关重要。

目录

第一章全球头颈癌药物市场简介

  • 市场概览
  • 分析范围
  • 先决条件

第二章执行摘要

第三章 已验证的市场研究分析方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球头颈癌药物市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球头颈癌药物市场（按治疗药物）

  • 概述
  • PD抑制剂
  • 微管抑制剂
  • EGFR抑制剂

6. 全球头颈癌药物市场（依治疗类型）

  • 概述
  • 外科治疗
  • 放射线治疗
  • 标靶治疗
  • 免疫疗法
  • 化疗

7. 全球头颈癌药物市场（依给药途径）

  • 概述
  • 注射
  • 口服

8. 全球头颈癌药物市场（依最终用户）

  • 概述
  • 零售和专业药房
  • 医院药房
  • 网路药局

9. 全球头颈癌药物市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他地区 (ROW)
    • 拉丁美洲
    • 中东和非洲

第十章全球头颈癌药物市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十一章 公司简介

  • Bristol-Myers Squibb
  • Merck & Co
  • Eli Lilly
  • Sanofi
  • Merck Group
  • AstraZeneca
  • Pfizer
  • Kura Oncology
  • Lion Biotechnologies

第十二章 附录

    • 相关分析
简介目录
Product Code: 58786

Head And Neck Cancer Drugs Therapeutics Market Size And Forecast

Head And Neck Cancer Drugs Therapeutics Market size was valued at USD 1.93 Billion in 2024 and is projected to reach USD 3.39 Billion by 2032, growing at a CAGR of 7.30% from 2026 to 2032.

The head and neck cancer drugs therapeutics encompasses a range of pharmaceutical treatments specifically designed for the management and treatment of cancers that occur in the head and neck region, including the oral cavity, pharynx, larynx, and nasal passages.

This includes various therapeutic categories, such as chemotherapy, immunotherapy, targeted therapy, and radiation therapy.

These drugs are used primarily in oncology to treat patients diagnosed with head and neck cancers, which are often associated with risk factors such as tobacco use, alcohol consumption, and human papillomavirus (HPV) infection.

The increasing prevalence of these cancers globally underscores the importance of this market, as effective treatment options are crucial for improving patient outcomes.

The rising awareness of head and neck cancers and advancements in precision medicine are propelling the demand for targeted therapies, making this market vital in addressing a significant health concern worldwide.

Global Head and Neck Cancer Drugs Therapeutics Market Dynamics

The key market dynamics that are shaping the global head and neck cancer drugs therapeutics market include:

Key Market Drivers

Rising Incidence of Head and Neck Cancers: According to the National Cancer Institute (NCI), an estimated 66,470 new cases of oral cavity, pharyngeal, and laryngeal cancers were diagnosed in the United States in 2024, representing approximately 3.4% of all new cancer cases. The increasing prevalence of head and neck cancers due to lifestyle factors such as smoking, alcohol consumption, and HPV infections is significantly driving demand for therapeutics.

Advancements in Treatment Options: Continuous innovations in drug development, particularly in targeted therapies and immunotherapies, are improving treatment efficacy, leading to higher adoption rates.

Growing Awareness and Screening Programs: Increased public awareness of head and neck cancers and initiatives promoting early detection and regular screenings are encouraging more patients to seek therapeutic options.

Increasing Research and Development Investments: Pharmaceutical companies are allocating significant resources to research and clinical trials for novel treatment modalities, stimulating market growth.

Improved Healthcare Infrastructure: The enhancement of healthcare facilities and oncology services, especially in developing regions, is facilitating access to cancer therapeutics and contributing to market expansion.

Key Challenges

High Treatment Costs: The elevated costs associated with advanced cancer therapies can limit patient access and result in disparities in treatment availability.

Side Effects and Toxicity: The potential for severe side effects and long-term toxicity associated with certain cancer drugs hinder patient adherence to treatment regimens.

Regulatory Hurdles: Stringent regulations and lengthy approval processes for new therapeutics can delay market entry and impede timely patient access to innovative treatments.

Limited Awareness in Emerging Markets: In many developing countries, insufficient awareness and inadequate healthcare infrastructure can restrict the adoption of available therapeutics.

Competition from Alternative Therapies: The rise of alternative treatment options, including natural and complementary therapies, can pose challenges for conventional cancer therapeutics.

Key Trends

Shift Towards Personalized Medicine: A growing emphasis on personalized treatment plans based on individual genetic profiles and biomarkers is enhancing the efficacy of head and neck cancer therapies.

Integration of Technology in Treatment: The incorporation of digital health technologies and telemedicine is improving patient management and adherence to treatment regimens.

Collaboration and Partnerships: Increased collaboration between pharmaceutical companies, research institutions, and healthcare providers is accelerating drug development and fostering innovation.

Focus on Combination Therapies: The trend of using combination therapies, which leverage multiple treatment modalities, is gaining popularity due to improved patient outcomes and reduced resistance.

Rising Use of Biomarker Testing: The growing utilization of biomarker testing for patient stratification is becoming essential for determining the most effective treatment approaches in head and neck cancer.

Global Head and Neck Cancer Drugs Therapeutics Market Regional Analysis

Here is a more detailed regional analysis of the global head and neck cancer drugs therapeutics market:

North America

North America is substantially dominating the Global Head and Neck Cancer Drugs Therapeutics Market and is expected to continue its dominance throughout the forecast period.

According to the American Cancer Society, an estimated 54,540 new cases of head and neck cancers are expected in the U.S. annually, highlighting the urgent need for effective treatment solutions.

The American Society of Clinical Oncology reports that since the FDA approval of pembrolizumab in 2016, the overall survival rate for patients with recurrent or metastatic head and neck squamous cell carcinoma has improved by 37%, compared to standard chemotherapy.

The North American market benefits from a well-established healthcare infrastructure, advanced research facilities, and significant investments in research and development by leading pharmaceutical companies.

This region is home to numerous biotech and pharmaceutical firms actively engaged in developing innovative therapies, including targeted treatments and immunotherapies specifically designed for head and neck cancers.

The presence of extensive clinical trial networks and regulatory agencies, such as the FDA, facilitates the timely approval and commercialization of new drugs.

The growing awareness of head and neck cancers and the availability of comprehensive treatment options contribute to an increasing patient population seeking therapies.

The North American market also faces challenges, including high treatment costs and the potential for disparities in access to care.

Despite these hurdles, the ongoing advancements in treatment modalities and the focus on personalized medicine position the North American head and neck cancer therapeutics market for sustained growth in the coming years.

Asia Pacific

Asia Pacific is anticipated to be the fastest-growing region in the Global Head and Neck Cancer Drugs Therapeutics Market during the forecast period.

The increasing prevalence of head and neck cancers in countries like India, China, and Japan significantly contributes to the growing demand for effective treatment options.

In particular, the rise in tobacco and alcohol consumption, coupled with poor oral hygiene practices, has heightened the incidence of these cancers in the region.

The Asia-Pacific market is characterized by a rapidly evolving healthcare infrastructure, with substantial investments in healthcare facilities and services.

Governments in various countries are actively promoting cancer awareness campaigns and improving access to treatment, which is expected to lead to early diagnosis and better therapeutic outcomes.

The region also witnesses a surge in clinical trials focusing on innovative therapies, including targeted therapies and immunotherapies, tailored to the genetic and environmental factors prevalent in the population.

Partnerships between local pharmaceutical companies and global biotech firms are fostering research and development, accelerating the introduction of novel therapeutics into the market.

Global Head And Neck Cancer Drugs Therapeutics Market: Segmentation Analysis

The Global Head And Neck Cancer Drugs Therapeutics Market is Segmented on the basis of Therapeutic, Therapy Type, Route of Administration, End-User, and Geography.

Head And Neck Cancer Drugs Therapeutics Market, By Therapeutic

  • PD Inhibitors
  • Microtubule Inhibitors
  • EGFR Inhibitors

Based on the Therapeutic Category, the Global Head and Neck Cancer Drugs Therapeutics Market is categorized into PD Inhibitors, Microtubule Inhibitors, and EGFR Inhibitors. The PD Inhibitors segment is experiencing significant growth owing to their role in enhancing the immune response against cancer cells by blocking programmed cell death pathways. This has led to improved survival rates for patients with head and neck cancers.

Head And Neck Cancer Drugs Therapeutics Market, By Therapy Type

  • Surgery
  • Radiation Therapy
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy

Based on the Therapy Type, the Global Head and Neck Cancer Drugs Therapeutics Market is segmented into Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, and Chemotherapy. The Surgery segment dominates the market as surgery remains a primary treatment option, often employed to remove tumors and surrounding tissues, playing a crucial role in early-stage head and neck cancers.

Head And Neck Cancer Drugs Therapeutics Market, By Route of Administration

  • Injectable
  • Oral

Based on the Route of Administration, the Global Head and Neck Cancer Drugs Therapeutics Market is categorized into Injectable and Oral. Injectable segment dominates in the market. Injectable treatments are widely utilized in this market due to their rapid onset of action and ability to deliver higher concentrations of drugs directly into the bloodstream or tumors, ensuring effective management of cancer symptoms and treatment outcomes. This method is particularly important for medications that require close monitoring and precise dosing, such as chemotherapy and targeted therapies.

Head And Neck Cancer Drugs Therapeutics Market, By End User

  • Retail & Specialty Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Based on the End User, the Global Head and Neck Cancer Drugs Therapeutics Market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment significantly dominates in this market, as they provide essential medications directly to patients undergoing treatment in healthcare facilities. These pharmacies are often equipped to handle complex drug regimens, ensuring timely access to necessary therapies for managing head and neck cancer.

Head And Neck Cancer Drugs Therapeutics Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the Global Head and Neck Cancer Drugs Therapeutics Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is substantially dominating the Global Head and Neck Cancer Drugs Therapeutics Market and is expected to continue its dominance throughout the forecast period. According to the American Cancer Society, an estimated 54,540 new cases of head and neck cancers are expected in the U.S. annually, highlighting the urgent need for effective treatment solutions. The American Society of Clinical Oncology reports that since the FDA approval of pembrolizumab in 2016, the overall survival rate for patients with recurrent or metastatic head and neck squamous cell carcinoma has improved by 37%, compared to standard chemotherapy.

Key Players

The "Global Head and Neck Cancer Drugs Therapeutics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bristol-Myers Squibb, Merck & Co., Eli Lilly, Sanofi, Merck Group, AstraZeneca, Pfizer, Kura Oncology, and Lion Biotechnologies.

  • This section offers in-depth analysis through a company overview, position analysis, the regional and industrial footprint of the company, and the ACE matrix for insightful competitive analysis. The section also provides an exhaustive analysis of the financial performances of mentioned players in the given market.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Head And Neck Cancer Drugs Therapeutics Market Key Developments

  • In April 2024, the OICR announced the launch of two new clinical trials as part of its Window-of-Opportunity (WOO) Network, which brought together Ontario researchers, doctors, and patients to investigate the biology of newly diagnosed and recurring malignancies.
  • In March 2024, 3T Biosciences ("3T"), an immunotherapy company that aimed to change the future of treatment for solid tumors and other immune-mediated diseases, announced that it had formed multiple new collaborations with leading academic centers and principal investigators to fuel 3T's best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) pHLA target discovery platform.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY THERAPEUTIC

  • 5.1 Overview
  • 5.2 PD Inhibitors
  • 5.3 Microtubule Inhibitors
  • 5.4 EGFR Inhibitors

6 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY THERAPY TYPE

  • 6.1 Overview
  • 6.2 Surgery
  • 6.3 Radiation Therapy
  • 6.4 Targeted Therapy
  • 6.5 Immunotherapy
  • 6.6 Chemotherapy

7 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 7.1 Overview
  • 7.2 Injectable
  • 7.3 Oral

8 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY END-USER

  • 8.1 Overview
  • 8.2 Retail & Specialty Pharmacies
  • 8.3 Hospital Pharmacies
  • 8.4 Online Pharmacies

9 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Rest of the World
    • 9.5.1 Latin America
    • 9.5.2 Middle East and Africa

10 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Development Strategies

11 COMPANY PROFILES

  • 11.1 Bristol-Myers Squibb
    • 11.1.1 Overview
    • 11.1.2 Financial Performance
    • 11.1.3 Product Outlook
    • 11.1.4 Key Developments
  • 11.2 Merck & Co
    • 11.2.1 Overview
    • 11.2.2 Financial Performance
    • 11.2.3 Product Outlook
    • 11.2.4 Key Developments
  • 11.3 Eli Lilly
    • 11.3.1 Overview
    • 11.3.2 Financial Performance
    • 11.3.3 Product Outlook
    • 11.3.4 Key Developments
  • 11.4 Sanofi
    • 11.4.1 Overview
    • 11.4.2 Financial Performance
    • 11.4.3 Product Outlook
    • 11.4.4 Key Developments
  • 11.5 Merck Group
    • 11.5.1 Overview
    • 11.5.2 Financial Performance
    • 11.5.3 Product Outlook
    • 11.5.4 Key Developments
  • 11.6 AstraZeneca
    • 11.6.1 Overview
    • 11.6.2 Financial Performance
    • 11.6.3 Product Outlook
    • 11.6.4 Key Developments
  • 11.7 Pfizer
    • 11.7.1 Overview
    • 11.7.2 Financial Performance
    • 11.7.3 Product Outlook
    • 11.7.4 Key Developments
  • 11.8 Kura Oncology
    • 11.8.1 Overview
    • 11.8.2 Financial Performance
    • 11.8.3 Product Outlook
    • 11.8.4 Key Developments
  • 11.9 Lion Biotechnologies
    • 11.9.1 Overview
    • 11.9.2 Financial Performance
    • 11.9.3 Product Outlook
    • 11.9.4 Key Developments

12 Appendix

    • 12.1.1 Related Research